2022 JAN 26 (NewsRx) — By a News Reporter – Staff News Editor at Information Technology Business Daily — New oncology research — Brain cancer is the subject of a report. According to reports from Seoul, South Korea, by NewsRx reporters, the research said, “Zolpidem is one of the most commonly prescribed hypnotics for the treatment of insomnia worldwide. However, there are numerous reports of a positive association between zolpidem and mortality, including an association with increased cancer-specific mortality found in a Taiwanese cohort study.
Journalists got a citation from the research of Seoul National University Hospital“This study aimed to determine the association between zolpidem use and brain cancer-specific mortality in patients with brain cancer. This retrospective population-based cohort study analyzed data National Health Insurance Service database. All incident cases of brain cancer at age 18 at the time of brain cancer diagnosis over a 15-year period (2003-2017) were included. Cox multivariate regression analysis after adjusting for covariates was performed to assess associations of zolpidem exposure with brain cancer-specific and all-cause mortality. This study identified 38,037 incident cases of brain cancer, of which 11,823 (31.1%) patients were exposed to zolpidem. In the multivariate Cox regression model, the brain cancer-specific mortality rate was significantly higher in patients prescribed zolpidem than in those not prescribed zolpidem (adjusted relative risk [HR]=1.14, 95% confidence interval [CI]=1.08-1.21,
According to the reporters, the research concluded, “Further prospective studies are warranted to understand the mechanism underlying the effect of zolpidem on mortality in patients with brain cancer.”
This research has been peer reviewed.
For more information on this research, see: Association of Zolpidem with Increase in mortality in patients with Brain cancer: A retrospective cohort study based on the National Health Insurance Service database. Journal of Clinical Neurology2022;18(1):65-70. Journal of Clinical Neurology can be contacted at: Korean Neurological Association1111 Daeil Bld, 43 Insa-Dong, Jongno-Gu, Seoul110-741, South Korea.
Our press correspondents advise that further information may be obtained by contacting Son Hyoshin, Department of Neurology, Seoul National University Hospital, Seoul, South Korea. Other authors of this research include Sungeun Hwang, Manho Kim, Sang Kun Lee and Ki Young Jung.
The editor of the Journal of Clinical Neurology can be contacted at: Korean Neurological Association1111 Daeil Bld, 43 Insa-Dong, Jongno-Gu, Seoul110-741, South Korea.
(Our reports provide factual information on research and discoveries from around the world.)